AbbVie
ABBV
282.68
-2.74
-0.96%
AbbVie
US · ABBV
#30 by market cap
Listed 1970
282.68
-2.74
-0.96%
Live - 5344 symbols - heartbeat 127s ago
· 2026-10-20 06:34
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 13 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 76.71% -0.09pp
- Institutions
- 4,742 -13
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund63.05%
Public Company5.38%
Private Company2.25%
Government Pension Fund2.00%
Sovereign Wealth Fund1.53%
Hedge Fund1.24%
Family Office/Trust0.51%
Insurance Company0.34%
Corporate Pension Plan0.19%
Other23.51%
Top holders as of 2026-06-30
BlackRock
8.46% · 149.49M sh
Vanguard Capital Management, LLC
7.09% · 125.34M sh
State Street Global Advisors
4.67% · 82.60M sh
Capital Research
3.71% · 65.57M sh
Vanguard Portfolio Management, LLC
2.74% · 48.48M sh
Other
73.32%
Geode Capital Management, LLC
2.66% · 47.00M sh
J.P. Morgan Asset Management, Inc.
1.93% · 34.06M sh
UBS Asset Management
1.53% · 27.11M sh
Norges Bank Investment Management
1.45% · 25.55M sh
Morgan Stanley
1.35% · 23.81M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 37 buys · 13 sells
| Name | Role | Stake |
|---|---|---|
| Richard Gonzalez | Chairperson & CEO | 0.02% |
| Azita Saleki | Chief Operating Officer | 0.01% |
| Robert Michael | President | 0.01% |
| Thomas Freyman | Independent Director | 0.01% |
| Jeffrey Stewart | Executive Vice President | 0.00% |
| Nicholas Donoghoe | Executive VP and Chief Business & Strategy Officer | 0.00% |
| Roopal Thakkar | SVP of Development & Regulatory Affairs and Chief Medical Officer | 0.00% |
| Scott Reents | Chief Financial Officer | 0.00% |
| Glenn Tilton | Lead Independent Director | 0.00% |
| Edward Rapp | Independent Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | Edward Rapp | Independent Director | Other Derivative Acquisition | +129 | $261.59 |
| 2026-09-29 | Susan Quaggin | Independent Director | Other Derivative Acquisition | +59 | $261.59 |
| 2026-08-13 | Nicholas Donoghoe | Executive VP and Chief Business & Strategy Officer | Derivative Exercise and Sale | -32,710 | $79.02–250.00 |
| 2026-06-29 | Edward Rapp | Independent Director | Other Derivative Acquisition | +134 | $251.64 |
| 2026-06-29 | Susan Quaggin | Independent Director | Other Derivative Acquisition | +62 | $251.64 |
| 2026-05-07 | Roxanne Austin | Lead Independent Director | Other Acquisition | +1,118 | -- |
| 2026-05-07 | Thomas Freyman | Independent Director | Other Acquisition | +1,118 | -- |
| 2026-05-07 | Thomas Falk | Independent Director | Other Acquisition | +1,118 | -- |
| 2026-05-07 | Edward Rapp | Independent Director | Other Acquisition | +1,118 | -- |
| 2026-05-07 | William H. Burnside | Independent Director | Other Acquisition | +1,118 | -- |
| 2026-05-07 | Frederick Waddell | Independent Director | Other Acquisition | +1,118 | -- |
| 2026-05-07 | Melody Meyer | Independent Director | Other Acquisition | +1,118 | -- |
| 2026-05-07 | Brett Hart | Independent Director | Other Acquisition | +1,118 | -- |
| 2026-05-07 | Rebecca Roberts | Independent Director | Other Acquisition | +1,118 | -- |
| 2026-05-07 | Susan Quaggin | Independent Director | Other Acquisition | +1,118 | -- |
| 2026-05-07 | Jennifer Davis | Independent Director | Other Acquisition | +1,118 | -- |
| 2026-03-30 | Edward Rapp | Independent Director | Other Derivative Acquisition | +155 | $217.49 |
| 2026-03-30 | Robert Alpern | Former Independent Director | Other Derivative Acquisition | +35 | $217.49 |
| 2026-03-30 | Susan Quaggin | Independent Director | Other Derivative Acquisition | +71 | $217.49 |
| 2026-03-03 | David Purdue | Officer | Open Market Disposition | -5,230 | $233.56 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-20 06:34:35 · For reference only, not investment advice and not tailored to your situation.
patent cliff fears priced in years ago and the new drugs stepped up more than skeptics expected. dividend yield here is still doing a lot of the work for the stock.